The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Podoplanin: An emerging cancer biomarker and therapeutic target
Open accessAbstract
Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR‐T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Cited by
Cancer-associated venous thromboembolism
Khorana, A. A., Mackman, N., Falanga, A., Pabinger, I., Noble, S., Ageno, W., Moik, F., & Lee, A. Y. Y. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00336-y · Cited by 470
Functional significance of the platelet immune receptors GPVI and CLEC-2
Rayes, J., Watson, S. P., & Nieswandt, B. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122955 · Cited by 328
Self-citationSignaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives
Fang, Z., Meng, Q., Xu, J., Wang, W., Zhang, B., Liu, J., Liang, C., Hua, J., Zhao, Y., Yu, X., et al. (2023) · Cancer Communications · doi:10.1002/cac2.12392 · Cited by 280
Molecular control of PDPNhi macrophage subset induction by ADAP as a host defense in sepsis
Zhang, P., Wang, X., Yang, X., & Liu, H. (2025) · JCI Insight · doi:10.1172/jci.insight.186456 · Cited by 10
Metadata
- Authors
- Krishnan, H., Rayes, J., Miyashita, T., Ishii, G., Retzbach, E. P., Sheehan, S. A., Takemoto, A., Chang, Y., Yoneda, K., Asai, J., Jensen, L., Chalise, L., Natsume, A., & Goldberg, G. S.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2018-05
- Volume
- 109
- Issue
- 5
- Pages
- 1292-1299
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2792751203
- Cited by
- 190
- References
- 1
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Podoplanin: An emerging cancer biomarker and therapeutic target. https://app.cochat.ai/papers/10.1111/cas.13580
- The paper
- Krishnan, H., Rayes, J., Miyashita, T., Ishii, G., Retzbach, E. P., Sheehan, S. A., Takemoto, A., Chang, Y., Yoneda, K., Asai, J., Jensen, L., Chalise, L., Natsume, A., & Goldberg, G. S. (2018). Podoplanin: An emerging cancer biomarker and therapeutic target. Cancer Science. https://doi.org/10.1111/cas.13580
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
